Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients

Cancers

Joanna Bialek¹  Gerit Theil¹  Paolo Fornara¹ 

[1] Medical Faculty of Martin Luther, University Halle-Wittenberg, Clinic of Urology, 06120 Halle (Saale), Germany;

关键词: prostate cancer;    breast cancer;    circulating tumor cells;    treatment decisions;   

DOI  :  10.3390/cancers12123782

来源: DOAJ

【 摘 要 】

Prostate cancer and breast cancer are the most common cancers worldwide. Anti-tumor therapies are long and exhaustive for the patients. The real-time monitoring of the healing progression could be a useful tool to evaluate therapeutic response. Blood-based biosources like circulating tumor cells (CTCs) may offer this opportunity. Application of CTCs for the clinical diagnostics could improve the sequenced screening, provide additional valuable information of tumor dynamics, and help personalized management for the patients. In the past decade, CTCs as liquid biopsy (LB) has received tremendous attention. Many different isolation and characterization platforms are developed but the clinical validation is still missing. In this review, we focus on the clinical trials of circulating tumor cells that have the potential to monitor and stratify patients and lead to implementation into clinical practice.

【 授权许可】

Unknown